Streetbeat News

Products Services

BWAY

BrainsWay announced the publication of post-marketing analysis results on late-life depression in the Journal of Clinical Medicine. The study likely showcases the effectiveness of BrainsWay's technology in treating this condition, which could influence the company's reputation and potentially its financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:10 pm

CMPS

Compass Pathways co-founders George Goldsmith and Ekaterina Malievskaia have resigned from the board, effective March 29, 2024. David Norton will serve as interim chair while the company searches for a permanent replacement. The company highlights its progress in developing psilocybin treatment for treatment-resistant depression and its achievements under the leadership of Goldsmith and Malievskaia, including FDA Breakthrough Therapy Designation and successful financing rounds.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:09 pm

AGFY

Agrify Corporation (NASDAQ:AGFY) has signed a contract with Connecticut-based New England Edibles, dba SoundView, to provide a Turnkey Hydrocarbon Extraction and Lab Equipment Package. This package includes various extraction systems and services to assist SoundView in meeting compliance for operation in Connecticut. SoundView, a woman and veteran-owned startup, aims to process and manufacture cannabis products for the CT market. Agrify's support encompasses design, equipment, and training, facilitating SoundView's setup for extraction capabilities.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:08 pm

RVPH

Reviva Pharmaceuticals Holdings, Inc. (RVPH) is set to present the Phase 3 clinical trial data for Brilaroxazine, its treatment for schizophrenia, at the SIRS 2024 Annual Meeting on April 4. This marks a significant milestone in the development of Brilaroxazine and could have implications for its future commercial potential.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:07 pm

LPCN

Lipocine Inc. announced positive week 52 results from its LPCN 1148 Phase 2 study in patients with cirrhosis, meeting both primary and hepatic encephalopathy endpoints. This marks a significant milestone in the development of LPCN 1148 for treating cirrhosis.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:02 pm

AAPL

Gene Munster of Deepwater Asset Management predicts Apple Inc.'s WWDC 2024 will introduce significant changes in operating system design with a focus on generative AI, marking the most substantial shift since the 1980s. This includes potential upgrades to core apps and Siri. However, Munster notes Apple is playing catch-up in the generative AI space, with competitors like Microsoft and Google already advancing. Apple's recent acquisition of DarwinAI and possible licensing of Google's Gemini AI for iOS 18 suggest a major push into AI.

Portfolio Pulse from Rounak Jain

March 28, 2024 | 11:58 am

MNSO

MINISO announced the launch of a new pop-up store in Times Square, branding it as an IP-Paradise filled with a wide range of cuddly plush toys. This move is part of MINISO's strategy to expand its presence and attract more customers by leveraging popular intellectual properties.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:51 am

KPRX

Kiora Pharmaceuticals' shares surged following the announcement of presenting additional data from its ABACUS-1 trial of KIO-301 in retinitis pigmentosa at the ARVO 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:49 am

HBM

Hudbay Minerals Inc. anticipates its gold production to average 272,500 ounces annually over the next three years.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:36 am

HBM

Hudbay Minerals Inc. has projected its copper production to average 153,000 tonnes annually over the next three years. This forecast highlights the company's production capabilities and future plans in the copper industry.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:35 am